About Regentis Biomaterials
Regentis Biomaterials is a company based in Or Akiva (Israel) founded in 2004. It operates as a HealthTech. Regentis Biomaterials has raised $25 million across 5 funding rounds from investors including dsm-firmenich, European Union and Haisco Pharmaceutical Group. Regentis Biomaterials offers products and services including GelrinC. Regentis Biomaterials operates in a competitive market with competitors including Augmenix, AmacaThera, LifeSprout, Carbylan and Biosyntech, among others.
- Headquarter Or Akiva, Israel
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Regentis Biomaterials Ltd.
-
Annual Revenue
$51.03 K (USD)960as on Dec 31, 2018
-
Net Profit
$4.8 M0as on Dec 31, 2024
-
EBITDA
$932 K0as on Dec 31, 2024
-
Total Equity Funding
$25 M (USD)
in 5 rounds
-
Latest Funding Round
$60.96 K (USD), Grant
May 31, 2021
-
Investors
dsm-firmenich
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Regentis Biomaterials
Regentis Biomaterials is a publicly listed company on the AMEX with ticker symbol RGNT in USA. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Regentis Biomaterials
Regentis Biomaterials offers a comprehensive portfolio of products and services, including GelrinC. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A resorbable hydrogel implant for tissue regeneration used.
Funding Insights of Regentis Biomaterials
Regentis Biomaterials has successfully raised a total of $25M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $60.96 thousand completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $60,956
-
First Round
First Round
(14 May 2012)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2021 | Amount | Grant - Regentis Biomaterials | Valuation |
investors |
|
| Jun, 2019 | Amount | Grant - Regentis Biomaterials | Valuation |
investors |
|
| Jan, 2019 | Amount | Grant - Regentis Biomaterials | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Regentis Biomaterials
Regentis Biomaterials has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include dsm-firmenich, European Union and Haisco Pharmaceutical Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Early-stage venture capital firm investing in Israel and US
|
Founded Year | Domain | Location | |
|
A venture capital firm focused on life science investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Regentis Biomaterials
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Regentis Biomaterials
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Regentis Biomaterials Comparisons
Competitors of Regentis Biomaterials
Regentis Biomaterials operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Augmenix, AmacaThera, LifeSprout, Carbylan and Biosyntech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Hydrogel spacers are provided for prostate cancer radiation therapy.
|
|
| domain | founded_year | HQ Location |
Injectable hydrogel platform developed for therapeutic medical applications.
|
|
| domain | founded_year | HQ Location |
Synthetic soft tissue substitutes for cosmetics and reconstructive surgery
|
|
| domain | founded_year | HQ Location |
Hyaluronic acid polymers are developed into therapeutics for pain management.
|
|
| domain | founded_year | HQ Location |
Biotherapeutic thermogels are developed for tissue repair applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Regentis Biomaterials
Frequently Asked Questions about Regentis Biomaterials
When was Regentis Biomaterials founded?
Regentis Biomaterials was founded in 2004 and raised its 1st funding round 8 years after it was founded.
Where is Regentis Biomaterials located?
Regentis Biomaterials is headquartered in Or Akiva, Israel. It is registered at Or Akiva, Central District, Israel.
Is Regentis Biomaterials a funded company?
Regentis Biomaterials is a funded company, having raised a total of $25M across 5 funding rounds to date. The company's 1st funding round was a Grant of $698.25K, raised on May 14, 2012.
What is the annual revenue of Regentis Biomaterials?
Annual revenue of Regentis Biomaterials is $51.03K as on Dec 31, 2018.
What does Regentis Biomaterials do?
Regentis Biomaterials is engaged in developing and commercializing an innovative hydrogel platform for repairing damaged tissue. The companys primary focus is on orthopedic treatments using resorbable hydrogel implants to regenerate damaged or diseased tissue. Operations are centered in the healthcare sector, specifically in biotechnology and tissue engineering solutions.
Who are the top competitors of Regentis Biomaterials?
Regentis Biomaterials's top competitors include AmacaThera, Augmenix and LifeSprout.
What products or services does Regentis Biomaterials offer?
Regentis Biomaterials offers GelrinC.
Is Regentis Biomaterials publicly traded?
Yes, Regentis Biomaterials is publicly traded on AMEX under the ticker symbol RGNT.
Who are Regentis Biomaterials's investors?
Regentis Biomaterials has 9 investors. Key investors include dsm-firmenich, European Union, Haisco Pharmaceutical Group, TRDF, and EIC Fund.
What is Regentis Biomaterials's ticker symbol?
The ticker symbol of Regentis Biomaterials is RGNT on AMEX.